25-Hydroxy vitamin D levels and its relation to disease activity and cardiovascular risk factors in women with systemic lupus erythematosus

Egyptian Rheumatologist

Volumn 33, Issue 4, 2011, Pages 195-201

  Ezzat, Yasser ^a   Sayed, Safaa ^b   Gaber, Wafaa ^b   Mohey, Abeer M ^b   Kassem, Tamer Wahid ^b  

^a FAYOUM UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

25(OH) vitamin D; Coronary vascular disease; Systemic lupus erythematosus

Indexed keywords

25 HYDROXYVITAMIN D; AZATHIOPRINE; CHOLESTEROL; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; GLUCOSE; HYDROXYCHLOROQUINE; LOW DENSITY LIPOPROTEIN; STEROID; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 84880395953     PISSN: 11101164     EISSN: 20902433     Source Type: Journal    
DOI: 10.1016/j.ejr.2011.07.004     Document Type: Article

References (37)

1. Xiang W., Kong J., Chen S., Cao L.P., Qiao G., Zheng W., et al. Cardiac hyper trophy in vitamin D receptor knock out mice role of systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288(1):E125-E132.
2. Mathieu C., Adorini L. The coming of age of 1,25-dihydroxy vitamin D3 analogs as immunomodulatory agents trends. Mol Med 2002, 8(4):174-179.
3. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxy vitamin D in the United States: data from the 3rd National Health and Nutrition Exam Survey. Arch Intern Med 2007, 167(11):1159-1165.
4. Manzi S., Meilahn E.N., Rairie J.E., Conto C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am Epidemiol 1997, 145:408-415.
5. Huisman A.M., While K.P., Algra A., Harth M., Vieth K., Jacobs J.W., et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumalol 2001, 28:2535-2539.
6. Ruiz-Irastorza G., Gordo S., Olivares N., Egurbide M.V., Aguirre C. Changes in vitamin D levels in patients with systemic lupus: effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken) 2010, 62:1160-1165.
7. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutical consideration. Ann Rheum Dis 2007, 66:1137-1142.
8. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
9. Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F. 1,25-Dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998, 160:5314-5319.
10. Staeva-Vieira T.P., Freedman L.P. 1,25-Dihydroxyvitamin D3 inhibits IFN gamma and IL-4 levels during in vitro polarization of primary murine CD4+ T cells. J Immunol 2002, 168:1181-1189.
11. Forman J.P., Giovannucci E., Holmes M.D., Bischoff-Ferrari H.A., Tworoger S.S., Willett W.C., et al. Plasma 25-hydroxy vitamin D levels and risk of incident hypertension. Hypertension 2007, 49(5):1063-1069.
12. Lemire J.M., Ince A., Takushima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992, 12:143-148.
13. Cantorna M.T., Humpal-Winter J., DeLuca H.F. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune oncephalomyelitis in mice. J Nutr 1999, 129:1966-1971.
14. Cantorna M.T., Hayes C.E., DeLuoa H.F. 1,25-Dihydroxychole-calciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998, 128:68-72.
15. Zella I.B., McCary L.C., DeLuca H.F. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003, 417:77-80.
16. Cantorna M.T., Munsick C., Bemiss C., Mahon B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000, 130:2648-2652.
17. Becker A., Fischer R., Schneider M. Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z Rheumatol 2001, 60:352-358.
18. Kamen D., Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 2008, 20:532-537.
19. Hochberg M.E. Updating the American college of rheumatology revised criteria for the classification of SLE. Arthritis Rheum 1997, 40:1725.
20. Must A., Dallal G.E., Dietz W.H. Reference data for obesity 1991 85th and 95th percentiles of body mass index and triceps skin fold thickness. Am J Clin Nutr 1991, 53:839-846.
21. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992, 35:630-640. Committee on Prognosis Studies in SLE.
22. Kashgarian M. New approaches to clinical pathologic correlation in lupus nephritis. Am J Kidney Dis 1982, 2:164-169.
23. Manzi S., Seiner F., Sullon-Tyrrell K., Fitzgerald S.G., Rairie J.E., Tracy R.P. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51-60.
24. Melamed M.L., Michos E.D., Post W., Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168(15):1629-1637.
25. Chonchoi M., Scragg R. 25-hydroxy vitamin D, insulin resistance and kidney function in the third National Health and Nutrition Examination surgery. Kidney Int 2007, 71(2):134-139.
26. Klein R.G., Arnaud S.B., Callagher R., Deluca H.B., Riggs I.H. Intestinal calcium absorption in exogenous hypercatabolism. Role of 25-hydroxy vitamin D and corticosteroid dose. J Clin Invest 1977, 60:253-259.
27. Van der Meer I.M., Bots M.L., Hofman A., del Sol A.L., van der Kuip D.A., Witteman J.C. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004, 109:1089-1094.
28. Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., et al. Independent association of low serum 25-hydroxy vitamin D and 1,25 dihydroxy vitamin D levels with all cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340-1349.
29. Wu P.W., Rhew E.Y., Dyer A.R., Dunlop D.D., Langman C.B., Price H., et al. 25-Hydroxy vitamin D and cardiovascular risk factors in women with SLE. Arthritis Rheum 2009, 61(10):1387-1395.
30. Hsia J., Heiss G., Ren H., Allison M., Dolan N.C., Greeland P., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115:846-854.
31. Folsom A.R., Kronmal R.A., Detrano R.C., O'Leary D.H., Bild D.E., et al. Coronary artery calcification compared with carotid intima media thickness in the prediction of cardiovascular disease incidence. The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008, 168:1333-1339.
32. Hahn T.J., Halstead L.R., Haddad J.G. Serum 25(OH)D concentrations in patients receiving chronic corticosteroid therapy. J Clin Med 1977, 90:399-404.
33. Carre M., Ayigebe O., Miravet L., Rasnusseb H. The effect of prednisolone on the metabolism and actions of 25(OH)D and 1,25 dihydroxy vitamin D. Proc Natl Acad Sci USA 1974, 71:2996-3000.
34. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
35. Del Rincon L., O'Leary D.H., Haas R.W., Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004, 50:3813-3822.
36. O'Leary T.J., Jones G., Yip A., Lohnos D., Gohanim M., Yendt E.R. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986, 315:727-730.
37. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Borriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2008, 47:920-923.